GPC3 and neoplasm: Preclinical studies have demonstrated the efficacy of GPC3-targeting CAR-T cells in vitro and in vivo, resulting in effective elimination of GPC3-positive HCC cells, tumor regression, and prolonged survival in mouse models of HCC.